Pharmaron Beijing Co., Ltd.
300759
Kedudukan dalam Saham
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Harga Saham
$5.58
Modal Pasaran
$8.24B
Perubahan (1 hari)
-3.77%
Perubahan (1 tahun)
28.36%
Negara
CN
Perdagangan Pharmaron Beijing Co., Ltd. (300759)
Kategori
Healthcare
Pendapatan untuk Pharmaron Beijing Co., Ltd. (300759)
Pendapatan pada Jun 2026 TTM: $303.40M
Menurut laporan kewangan terkini Pharmaron Beijing Co., Ltd., pendapatan semasa syarikat ialah $303.40M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $286.51M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $259.64M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Pharmaron Beijing Co., Ltd. dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $303.40M | 10.98% |
| 2025 | $273.38M | -4.58% |
| 2024 | $286.51M | 10.35% |
| 2023 | $259.64M | 7.48% |
| 2022 | $241.58M | -19.65% |
| 2021 | $300.66M | 48.87% |
| 2020 | $201.96M | 122.33% |
| 2019 | $90.84M | 59.17% |
| 2018 | $57.07M | 33.32% |
| 2017 | $42.81M | 38.55% |
| 2016 | $30.90M | 129.26% |
| 2015 | $13.48M | 188.75% |
| 2014 | $4.67M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | 1,638.58% |
US
|
|
| $-3.09B | -1,117.46% |
US
|
|
| $-4.02B | -1,423.72% |
AU
|
|
| $3.01B | 890.67% |
BE
|
|
| $1.95B | 542.93% |
NL
|
